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ditorialngiotensin  II  receptor  blockers  for  patients  with  chronic  heart  failure:  The  next
tep  forwardThe renin–angiotensin–aldosterone system (RAAS) is central to
he pathogenesis of heart failure (HF) and medications inhibiting
AAS are critical. Angiotensin-converting enzyme (ACE) inhibitors
nd angiotensin receptor blockers (ARBs) both inhibit RAAS, but by
ifferent mechanisms. ACE inhibitors block an enzyme responsi-
le for converting angiotensin I to angiotensin II and for degrading
arious kinins. However, during chronic therapy, angiotensin II lev-
ls are not completely suppressed. Thus, in patients with chronic
F, despite treatment with ACE inhibitors angiotensin II levels may
emain elevated and even increase over time. ARBs block the effects
f angiotensin II on the angiotensin I receptor, independently of the
ource of angiotensin II production [1,2].
The Candesartan in Heart Failure: Assessment of Reduction in
ortality and Morbidity (CHARM)-Alternative trial prospectively
ested the effect of an ARB in an ACE inhibitor-intolerant population
f patients with chronic HF and left ventricular ejection fraction
LVEF) less than 40% [3].  Candesartan in these patients resulted in
 reduction in the composite endpoint of cardiovascular death or
ospital admission for HF from 40% in the control group to 33% in
he candesartan group over a mean follow-up of 33.7 months with
 trend toward decreased all-cause mortality. Subgroup analysis of
atients in the Valsartan in Heart Failure Trial (Val-HeFT) also found
hat patients (LVEF < 40%) intolerant to ACE inhibitors had fewer
F hospitalizations and a trend toward improved mortality with
he addition of valsartan [4].  Therefore, modern guidelines recom-
end that an ARB be used in ACE inhibitor-intolerant patients with
hronic HF and LVEF less than 40% [1,2]. ARBs should be titrated as
olerated, in conjunction with beta-blocker therapy, to target doses
sed in clinical trials.
In Japan, the randomized, double-blind, placebo-controlled
ssessment of Response to Candesartan in Heart Failure in Japan
ARCH-J) study evaluated the efﬁcacy and safety of 6-month treat-
ent with candesartan 8 mg  once daily in patients with congestive
F (LVEF ≤ 45%) who were not taking an ACE inhibitor [5].  The pri-
ary endpoint of the study was conﬁrmed progression of chronic
F including (1) patient hospitalization for the management of
hronic HF or (2) addition, or dosage increase, of any medications.
he primary endpoint was signiﬁcantly lower in the candesartan
roup than in the placebo group (7.4% vs. 22.2%). Based on these
esults, the indication for candesartan as treatment for mild to mod-
rate chronic HF in patients for whom ACE inhibitor administration
s inappropriate was approved in Japan in 2005.
DOI of original article: http://dx.doi.org/10.1016/j.jjcc.2012.12.004.
914-5087/$ – see front matter © 2013 Published by Elsevier Ltd on behalf of Japanese Co
ttp://dx.doi.org/10.1016/j.jjcc.2012.12.017A multicenter, open-label study was conducted by Matsuzaki
and colleagues to assess the efﬁcacy and safety of 60-week
treatment with candesartan in Japanese ACE inhibitor intolerant
patients with mild to moderate chronic HF [6].  The results are pub-
lished in the current issue of the journal. Primary efﬁcacy endpoints
were changes from baseline in plasma brain natriuretic peptide
(BNP), LVEF, end-diastolic dimension, and New York Heart Asso-
ciation (NYHA) functional class. This study was designed to closely
represent the clinical use of recommended doses of candesartan
in Japan. In most patients, the dose was increased from 4 mg  to
8 mg  at a time point between Week 4 and Week 12, in anticipa-
tion of the higher efﬁcacy of candesartan. The results showed no
change in either plasma BNP levels or LVEF from baseline at the
end of treatment period in the low-dose (LD: candesartan 2 or
4 mg)  group, whereas BNP and LVEF improved in the high-dose
(HD: candesartan 8 mg)  group. NYHA functional class improved
in both groups and no safety concerns were observed in either
group.
As a whole, this study supports the titration of candesartan
in Japanese patients. However, several points should be carefully
interpreted. First, the authors evaluated the efﬁcacy of candesar-
tan by employing surrogate markers. The deﬁnition of surrogate
marker is very strict and changes in the surrogate markers should
predict a change in the true endpoint, such as mortality and to
date, no perfect surrogate marker has been reported [7].  How-
ever, Anand et al. reported that not only is plasma BNP a predictor
of all-cause mortality and ﬁrst morbid event in patients with HF
but change in BNP over time was associated with corresponding
changes in all-cause mortality and ﬁrst morbid event in the Val-
HeFT [8].  Moreover, Kramer et al. recently reported the correlation
between therapy-induced changes in LV remodeling [changes in
LVEF, end-diastolic volume (EDV), and end-systolic volume (ESV)]
and longer-term outcomes in patients with LV dysfunction [9].
Taking these results into account, BNP and EF can to be used as
surrogate markers. Second, the mean LVEF was 56% in this study,
while being 30% in the CHARM-Alternative [3] and 27% in the Val-
HeFT [4]. Therefore, substantial numbers of patients apparently had
preserved EF. In contrast to the mortality improving effects seen
in patients with reduced EF, the CHARM-Preserved trial showed
no reduction in the primary composite endpoint (cardiovascular
death or HF hospitalization). However, candesartan had a moder-
ate impact in preventing admissions for HF in this population [10].
These effects may  explain the BNP decrease seen in this study. Third,
patients with HD had elevated blood pressure at baseline, the dura-
tion of HF was  relatively short, and the diuretic prescription rate
was low. As these characteristics are indicators of a good prognosis
llege of Cardiology.
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n HD patients, they might have inﬂuenced the improvements in
NP and LVEF.
How should we move ahead with this evidence? The next steps
hould be to tackle the goals of improving (1) the prescription
ate and (2) the prescription dose. First, studies have shown that
vidence-based, guideline-recommended therapies are sometimes
nderused in real-world management in a variety of cardiology
ractices and there is substantial variation in adherence with HF
uidelines in both hospital and ambulatory care settings. The Reg-
stry to Improve the Use of Evidence-Based Heart Failure Therapies
n the Outpatient Setting (IMPROVE HF) was designed to facilitate
elivery of evidence-based, guideline-recommended care to eli-
ible patients with reduced LVEF associated with chronic HF. At
aseline, an ACE inhibitor or ARB was prescribed in 80% of 14,000
ligible patients. However, there was marked variation from 5.9%
o 96.3% in actual practice [11]. The wide variation in care across
ractices may  reﬂect differences in training, guideline familiarity,
nd implementation of tools and systems to ensure that recom-
ended care is provided [12]. Successful strategies to improve the
mplementation of guidelines include hospital tool kits and edu-
ational opportunities (Table 1). Building a multidisciplinary team
s absolutely critical. Second, the prescribed dose of candesartan
s sometimes relatively low. In The Heart failure Endpoint Evalua-
ion of Angiotensin II Antagonist Losartan (HEAAL) study, losartan
50 mg  daily reduced the rate of death or admission for HF as
ompared with 50 mg  daily [13] (Fig. 1). These ﬁndings show the
alue of up-titrating ARB doses to achieve clinical beneﬁts, although
he outcome beneﬁts have to be weighed against several types of
dverse effects that can occur.
able 1
rocess-of-care improvement components.
Hospital tool kit Educational opportunities
Algorithms National and regional meetings
Critical pathways Latest evidence
Standardized orders Up-to-date outcomes
Patient education materials Guideline updates
Wall charts Newsletters
Pocket cards Best practice examples
Checklists Expert commentary
Build a hospital team
dapted from Peterson et al. [12].
ig. 1. Kaplan–Meier cumulative event curves for the primary composite endpoint
f  death or admission for heart failure.
dapted from Konstam et al. [13].
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In conclusion, high-dose candesartan should be considered in
patients with chronic HF and reduced EF, when tolerable. A system
that would improve the prescription rate and the prescription dose
is awaited.
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